Sold as Hipputope, Hippuran I 131, Iodohippurate Sodium I 131. Every FDA application for this active ingredient.
As of Nov 22, 2026, FDA lists 3 applications for Iodohippurate sodium I-131 (sold as Hipputope, Hippuran I 131, Iodohippurate Sodium I 131), first approved May 24, 1968, with 0 new uses approved and 0 published complete response letters.
| May 24, 1968 | Hippuran I 131NDA 16666 · New formulation or manufacturer | Mallinckrodt | 7 | Discontinued |
| Jun 25, 1970 | HipputopeNDA 15419 · New formulation or manufacturer | Bracco Imaging | 5 | Discontinued |
| — | Iodohippurate Sodium I 131NDA 17313 | Pharmalucence | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA